26. HTLV-1-associated myelopathy Clinical trials / Disease details
Clinical trials : 29 / Drugs : 47 - (DrugBank : 29) / Drug target genes : 34 - Drug target pathways : 119
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03191526 (ClinicalTrials.gov) | May 22, 2017 | 13/6/2017 | A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM) | A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM) | HTLV-1 Associated Myelopathy | Drug: KW-0761 0.3 mg/kg IV;Drug: Placebo (saline) | Kyowa Kirin Co., Ltd. | NULL | Terminated | 20 Years | N/A | All | 66 | Phase 3 | Japan |